NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT (COVID-19)

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: ROB  CAUDLE
Organization: DUKE UNIVERSITY
Fiscal Year: 2020
Award: $996,432
Funding agency: National Institute of Allergy and Infectious Diseases

The mission of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID) is to ensure an end to the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic by supporting research that can lead to the development of therapies, vaccines, and prevention strategies. Nonhuman primate (NHP) models present the opportunity to test a variety of candidate AIDS vaccines, optimizing their ability to elicit immune responses and testing their ability to prevent infection or to control virus replication after virus challenge. DAIDS provides immunological and virological support for NHP studies conducted at NIAID’s Simian Vaccine Evaluation Unit (SVEU) contract sites and by AIDS vaccine researchers through three Nonhuman Primate Immunology and Virology Laboratories for AIDS Vaccine Research and Development (NHP Core Labs) contracts. The objective of these Core Laboratories has been to ensure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines.  This project focuses specifically on SARS-CoV-2 (COVID-19) neutralization assays and other assays to evaluate antibody responses of NHPs to candidate SARS-CoV-2 vaccines.

Terms: <2019 novel coronavirus><2019-nCoV><AIDS><AIDS Vaccines><AIDS Virus><AIDS vaccine><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Acquired Immunologic Deficiency Syndrome><Antibody Response><Assay><Bioassay><Biologic Assays><Biological Assay><COVID-19><COVID19><Contracting Opportunities><Contracts><Development><Development and Research><Ensure><Epidemic><HIV><HIV/SIV vaccine><Human Immunodeficiency Viruses><Immune response><Immunize><Immunochemical Immunologic><Immunologic><Immunologic Tests><Immunological><Immunological Tests><Immunological response><Immunologically><Immunologics><Immunology><Infection prevention><Investigators><LAV-HTLV-III><Laboratories><Lead><Lymphadenopathy-Associated Virus><Mission><Modeling><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Pb element><Prevent infection><Preventative strategy><Prevention strategy><Preventive strategy><R & D><R&D><Research Personnel><Research Support><Researchers><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><Site><Standardization><Testing><United States National Institutes of Health><Vaccine Research><Vaccines><Virus><Virus Replication><Virus-HIV><Wuhan coronavirus><corona virus disease 2019><coronavirus disease 2019><develop therapy><developmental><heavy metal Pb><heavy metal lead><host response><immunogenicity><immunoresponse><intervention development><non-human primate><nonhuman primate><pre-clinical><preclinical><research and development><therapy development><treatment development><vaccine evaluation><vaccine screening><vaccine testing><viral multiplication><viral replication><virology><virus multiplication>